GAMMA Investing LLC increased its position in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 26,284.3% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 122,951 shares of the medical equipment provider's stock after purchasing an additional 122,485 shares during the period. GAMMA Investing LLC owned approximately 0.23% of Masimo worth $20,484,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC increased its holdings in shares of Masimo by 152.6% in the 3rd quarter. Barclays PLC now owns 39,957 shares of the medical equipment provider's stock valued at $5,329,000 after purchasing an additional 24,137 shares in the last quarter. Blue Trust Inc. grew its position in Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after buying an additional 71 shares during the period. Greenleaf Trust purchased a new position in Masimo in the fourth quarter valued at about $208,000. Trust Point Inc. acquired a new stake in shares of Masimo during the 4th quarter valued at approximately $230,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Masimo by 0.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 373,705 shares of the medical equipment provider's stock worth $61,773,000 after acquiring an additional 1,522 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.
Insider Activity at Masimo
In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares in the company, valued at $2,754,601.53. The trade was a 11.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Bilal Muhsin sold 10,000 shares of the stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $163.28, for a total transaction of $1,632,800.00. Following the transaction, the chief operating officer now owns 24,172 shares in the company, valued at approximately $3,946,804.16. The trade was a 29.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 9.70% of the company's stock.
Analysts Set New Price Targets
Several equities analysts recently weighed in on the company. BTIG Research set a $193.00 price objective on Masimo and gave the company a "buy" rating in a research note on Wednesday, May 7th. Raymond James dropped their price target on Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Wells Fargo & Company decreased their price objective on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Needham & Company LLC restated a "hold" rating on shares of Masimo in a report on Thursday, April 10th. Finally, Wall Street Zen downgraded shares of Masimo from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Masimo currently has a consensus rating of "Moderate Buy" and a consensus target price of $191.60.
Get Our Latest Stock Report on Masimo
Masimo Price Performance
MASI stock traded down $0.09 during trading on Monday, hitting $171.88. The stock had a trading volume of 787,546 shares, compared to its average volume of 645,921. The stock has a market cap of $9.32 billion, a price-to-earnings ratio of 118.54 and a beta of 1.19. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The company's 50 day moving average price is $157.06 and its two-hundred day moving average price is $167.29. Masimo Co. has a 1-year low of $101.61 and a 1-year high of $194.88.
Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, beating analysts' consensus estimates of $1.24 by $0.12. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $372.00 million during the quarter, compared to analyst estimates of $367.79 million. During the same quarter in the previous year, the business posted $0.77 earnings per share. The company's revenue was down 24.5% on a year-over-year basis. On average, sell-side analysts forecast that Masimo Co. will post 4.1 EPS for the current fiscal year.
About Masimo
(
Free Report)
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
Read More

Before you consider Masimo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Masimo wasn't on the list.
While Masimo currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.